The product ist he second regenerative medicine product registered in Japan. It is listed by health insurances and used fort he treatment of traumatic cartilage deficiency or osteochondritis dissecans in knee joints. Chondrocytes are harvested from the joint oft he patent, and with atelocollagen as scaffold expanded for 4 weeks, then transplanted by surgery. Sales are disappointing as these indicateions are severely limited.
Nikkei Biotech news release, April 17, 2015